RFXANK and combined immunodeficiency: Genetic studies of patients with combined immunodeficiency (CID) with predominant CD4 cell deficiency have revealed mutations in genes encoding regulatory factors of the expression of MHC class II molecules such as CIITA, RFXANK, RFX5 or RFXAP [5–9].